TIA
ESPR

Traphagen Investment Advisors’s Esperion Therapeutics ESPR Stock Holding History

Traphagen Investment Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,200
Closed -$26.7K – 185
2024
Q3 		$26.7K Buy
+16,200
New +$32.7K ﹤0.01% 173

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Traphagen Investment Advisors's ESPR Position: Q4 2024 in Review

Traphagen Investment Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2024, closing a stake of 16,200 shares — an estimated $26.7K sold.

Traphagen Investment Advisors first reported a position in ESPR in Q3 2024 and held it in 1 quarter. The position peaked at $26.7K in Q3 2024. 189 funds tracked by Wall St. Rank hold ESPR as of Q4 2024.

  • Traphagen Investment Advisors reported no remaining Esperion Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Traphagen Investment Advisors sold 16,200 Esperion Therapeutics shares in Q4 2024, an estimated $26.7K.
  • Traphagen Investment Advisors first reported a position in Esperion Therapeutics in Q3 2024 and held it in 1 quarter.
  • Traphagen Investment Advisors's Esperion Therapeutics position peaked at $26.7K in Q3 2024.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2024.

Based on Traphagen Investment Advisors's 13F filing for Q4 2024, filed 17 Jan 2025.